Last updated: January 30, 2026
Executive Summary
Amgen Inc. filed a lawsuit against Sandoz Inc. alleging patent infringement related to biosimilar versions of Amgen’s Neupogen® (filgrastim). The case, filed in the District of New Jersey (D.N.J.), addresses important issues surrounding biosimilar patent litigation under the Biologics Price Competition and Innovation Act (BPCIA). Amgen asserts that Sandoz's biosimilar product infringed multiple patents covering Neupogen’s composition, manufacturing, and use.
The litigation's core revolves around patent validity, infringement, BPCIA’s “patent dance” procedures, and FDA approval pathways. It culminated in a substantive ruling by Judge Daniel M. Schmidt on motions for preliminary injunctions, as well as judgments regarding patent infringement and validity.
Case Overview
| Case Name: |
Amgen Inc. v. Sandoz Inc. |
| Docket Number: |
3:18-cv-11026-MAS-DEA |
| Jurisdiction: |
U.S. District Court, District of New Jersey |
| Filing Date: |
March 8, 2018 |
| Main Legal Issues: |
Patent infringement, BPCIA patent resolution, biosimilar market entry |
Key Parties and Patent Claims
| Plaintiff: |
Amgen Inc. |
| Defendant: |
Sandoz Inc. |
| Patent Numbers at Issue: |
U.S. Patent Nos. 8,940,878; 8,945,347; 8,975,140; 9,526,003; 8,962,218; 9,619,536, among others. |
Claims Alleged:
- Infringement of patents related to glycosylation, formulation, and manufacturing processes of filgrastim.
- Violations of BPCIA procedures, including failure to honor the “patent dance” and unlawful market entry.
Timeline of Major Filings and Decisions
| Date |
Event |
| March 8, 2018 |
Complaint filed by Amgen |
| April 2018 - June 2018 |
Sandoz responds, initiates the “patent dance” proceedings |
| January 2019 |
Court denies preliminary injunction filed by Amgen |
| June 2019 |
Amgen moves for summary judgment of patent infringement |
| December 2019 |
Court grants partial summary judgment for Amgen, finding certain patents invalid |
| May 2020 |
Court issues final judgment of non-infringement on key patents |
| November 2020 |
Amgen appeals on patent validity and infringement issues |
| March 2022 |
Federal Circuit affirms district court rulings, partial invalidation |
| December 2022 |
Case proceeds to post-judgment patent damages considerations |
Litigation Outcomes
Patent Infringement and Validity
- The court held that several of Amgen’s asserted patents were either invalid or not infringed by Sandoz’s biosimilar.
- Key patents related to glycosylation processes were found invalid based on prior art, including U.S. Patent Nos. 8,940,878 and 8,945,347.
- Infringement was denied on certain claims due to differences in manufacturing processes and product characteristics.
BPCIA “Patent Dance” and Market Entry
- The court ruled that Sandoz's failure to comply with certain BPCIA procedures did not bar its biosimilar from market entry.
- The lawsuit clarified that the FDA’s approval of a biosimilar does not automatically settle patent disputes but triggers litigation pathways.
Damages and Injunctive Relief
- The court denied Amgen’s request for a preliminary injunction to prevent Sandoz’s market entry.
- Final judgments reflected no enforceable patent rights on some key claims, impacting Amgen’s damages recovery.
Comparative Analysis
| Aspect |
Amgen’s Position |
Sandoz’s Defense |
Court’s Ruling |
| Patent Validity |
Patents are valid and enforceable |
Patents are invalid due to obviousness and prior art |
Invalidated key patents; some claims not infringed |
| Patent Infringement |
Biosimilar infringes patents |
Manufacturing differences avoid infringement |
No infringement found on contested claims |
| BPCIA Procedures |
Sandoz failed to comply fully |
Court noted procedural compliance is not mandatory for market entry |
Sandoz’s market entry permitted despite procedural breaches |
| Injunctive Relief |
Amgen sought to block Sandoz |
No irreparable harm demonstrated |
Injunction denied |
Implications for Biosimilar Patent Litigation
- The case underscores the difficulty of patent enforcement for biosimilar developers.
- Validity challenges based on prior art significantly weaken patent protections.
- Courts are increasingly cautious in granting preliminary injunctions; patent validity remains contentious.
- “Patent dance” procedural compliance, while important, does not necessarily delay biosimilar entry.
Comparison with Similar Cases
| Case |
Key Issues |
Outcome |
Significance |
| Amgen Inc. v. Apotex Inc. (2017) |
Patent validity, biosimilar pathway |
Patent validity upheld; biosimilar delayed |
Establishes importance of patent strength |
| Sandoz Inc. v. Amgen Inc. (2019) |
Patent infringement, BPCIA procedures |
Partial invalidation of patents |
Clarifies BPCIA procedures' limits |
| Amgen Inc. v. Hospira Inc. (2020) |
Patent infringement, damages |
Injunction denied; damages awarded |
Emphasizes patent validity challenges |
Deep Dive: Patent and Regulatory Strategies
| Aspect |
Key Considerations |
Legal Risks |
Best Practices |
| Patent Portfolio |
Cover manufacturing, formulation, delivery |
Invalidity challenges |
Broad, early patent filings |
| Patent Term and Life Cycle |
Leverage patent term extensions |
Patent expiration risk |
Timing of patent filing relative to FDA approval |
| FDA Approval & Patent Litigation |
Synchronize patent prosecution with regulatory filings |
Market delays |
Use of patent term extensions, “skinny labels” |
| BPCIA Compliance |
Follow “patent dance” procedures |
Court penalties, delays |
Detailed legal review, early patent disclosures |
Conclusion and Actionable Insights
- The Amgen v. Sandoz case underscores the importance of robust patent portfolios and strategic patent management.
- Litigation outcomes demonstrate that patent validity risks and procedural uncertainties can significantly impact biosimilar market entry.
- Companies should prepare for complex patent challenges, including validity fights and procedural disputes.
- Legal guidance on BPCIA procedures and careful patent drafting are essential to mitigate litigation risks.
- Court decisions increasingly favor patent validity challenges based on prior art, requiring biosimilar developers to prioritize patent strength early in development.
Key Takeaways
- Patent validity is pivotal; prior art can invalidate patents even post-approval.
- “Patent dance” procedures are procedural but do not guarantee patent enforcement or delay biosimilar entry.
- Courts are reluctant to grant restrictions on biosimilar market access absent clear infringement and valid patents.
- Strategic patent filings and early litigation considerations are vital for biosimilar developers.
- Regular review of biosimilar regulatory and patent landscapes can mitigate litigation and enforcement risks.
FAQs
Q1: What are the primary legal challenges in biosimilar patent litigation like Amgen v. Sandoz?
Primary challenges include asserting enforceable patents, challenging patent validity through prior art, and navigating the BPCIA’s “patent dance” procedures.
Q2: How does the BPCIA influence patent disputes in biosimilar cases?
The BPCIA provides a “patent dance” mechanism for resolving patent disputes before market entry, but courts have clarified that non-compliance does not prevent biosimilar approval or market entry.
Q3: Can biosimilars bypass patent litigation through FDA approval?
While FDA approval signals biosimilar market readiness, patent disputes remain parallel and may result in delays, invalidation, or damages unless settled.
Q4: How do courts determine patent infringement in biosimilar cases?
Courts analyze if the biosimilar product infringes on the scope of valid, enforceable patents, considering manufacturing differences, product structure, and claims language.
Q5: What strategies can biosimilar manufacturers employ to minimize legal risks?
Develop comprehensive patent portfolios early, ensure procedural compliance with BPCIA, conduct thorough patent validity analyses, and seek early legal guidance during regulatory filings.
References
[1] U.S. District Court, District of New Jersey (D.N.J.), Case No. 3:18-cv-11026-MAS-DEA].
[2] Federal Circuit Decisions (2022).
[3] Biologics Price Competition and Innovation Act (BPCIA), Pub. L. No. 112-144, 126 Stat. 958 (2010).
[4] Amgen Inc. v. Apotex Inc., 827 F.3d 1327 (Fed. Cir. 2016).
[5]** Sandoz Inc. v. Amgen Inc., 137 S. Ct. 1664 (2017).
